DK2938349T3 - Sammensætning til anvendelse som en støtteterapi til behandling af tumorer - Google Patents
Sammensætning til anvendelse som en støtteterapi til behandling af tumorer Download PDFInfo
- Publication number
- DK2938349T3 DK2938349T3 DK13828803.0T DK13828803T DK2938349T3 DK 2938349 T3 DK2938349 T3 DK 2938349T3 DK 13828803 T DK13828803 T DK 13828803T DK 2938349 T3 DK2938349 T3 DK 2938349T3
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- gel
- strain
- aloe
- dsm
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 238000011282 treatment Methods 0.000 title claims abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 title description 5
- 230000001580 bacterial effect Effects 0.000 claims abstract description 34
- 241000186684 Lactobacillus pentosus Species 0.000 claims abstract description 23
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940072056 alginate Drugs 0.000 claims abstract description 17
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 17
- 229920000615 alginic acid Polymers 0.000 claims abstract description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000011701 zinc Substances 0.000 claims abstract description 11
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 11
- 230000000973 chemotherapeutic effect Effects 0.000 claims abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 5
- 241001116389 Aloe Species 0.000 claims description 21
- 235000011399 aloe vera Nutrition 0.000 claims description 21
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 11
- 235000010413 sodium alginate Nutrition 0.000 claims description 11
- 229940005550 sodium alginate Drugs 0.000 claims description 11
- 239000000661 sodium alginate Substances 0.000 claims description 11
- 241000186000 Bifidobacterium Species 0.000 claims description 6
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 6
- 108090000237 interleukin-24 Proteins 0.000 claims description 6
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 4
- 229920001938 Vegetable gum Polymers 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 235000004509 Aloe arborescens Nutrition 0.000 description 14
- 240000007474 Aloe arborescens Species 0.000 description 14
- 102000013691 Interleukin-17 Human genes 0.000 description 13
- 108050003558 Interleukin-17 Proteins 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000008070 Interferon-gamma Human genes 0.000 description 6
- 229940044627 gamma-interferon Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 210000003238 esophagus Anatomy 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 108010062877 Bacteriocins Proteins 0.000 description 3
- 241000186869 Lactobacillus salivarius Species 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oncology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Sammensætning til anvendelse som støtteterapi i antitumor-kemoterapeutiske behandlinger; hvor nævnte sammensætning omfatter bakteriestammen Lactobacillus pentosus LPS01 med deponeringsnummer DSM 21980, deponeret 11.14.2008 af Probiotical SpA.
2. Sammensætningen til anvendelse ifølge krav 1, hvor nævnte sammensætning yderligere omfatter en yderst biotilgængelig zink internaliseret i en tyndaliseret bakteriestamme.
3. Sammensætningen til anvendelse ifølge krav 2, hvor nævnte tyndaliserede bakteriecelle er valgt fra gruppen omfattende stammen Streptococcus thermophilus ST16 BM DSM 19526 deponeret hos DSMZ den 07.13.2007 og stammen Bifidobacterium lactic Bb 1 DSM 17850 deponeret hos DSMZ den 12.23.2005.
4. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor nævnte sammensætning yderligere omfatter mindst en gummi, fortrinsvis en plantegummi.
5. Sammensætningen til anvendelse ifølge krav 4, hvor nævnte plantegummi er mindst et alginat, fortrinsvis natriumalginat.
6. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-5, hvor nævnte sammensætning yderligere omfatter mindst en gel.
7. Sammensætningen til anvendelse ifølge krav 6, hvor nævnte gel er en Aloebaseret gel, fortrinsvis en gel baseret på Aloe arborescens.
8. Sammensætningen til anvendelse ifølge krav 7, hvor nævnte Aloe-baserede gel er en gel baseret på Aloe arborescens i lyofiliseret form.
9. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 1-8, hvor nævnte sammensætning omfatter bakteriestammen Lactobacillus pentosus LPS01 med deponeringsnummer DSM 21980; mindst en bakteriestamme, der internaliserer zink-ionen, valgt fra gruppen omfattende stammen Streptococcus thermophilus ST16 BM med deponeringsnummer DSM 19526 og stammen Bifidobacterium lactic Bb 1 med deponeringsnummer DSM 17850; et alginat, fortrinsvis natriumalginat og et produkt baseret på Aloe arborescens, fortrinsvis i lyofiliseret form.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT002270A ITMI20122270A1 (it) | 2012-12-31 | 2012-12-31 | Terapia di supporto ai trattamenti di chemioterapia per i tumori, per la sindrome da immunodeficienza acquisita e per le leucemie. |
PCT/IB2013/002890 WO2014102595A1 (en) | 2012-12-31 | 2013-12-31 | Composition for use as a support therapy for treatment of tumours, aids and leukaemia |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2938349T3 true DK2938349T3 (da) | 2018-05-07 |
Family
ID=47720684
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13828803.0T DK2938349T3 (da) | 2012-12-31 | 2013-12-31 | Sammensætning til anvendelse som en støtteterapi til behandling af tumorer |
DK18157714.9T DK3345611T3 (da) | 2012-12-31 | 2013-12-31 | Støtteterapi til erhvervet immundefektsyndrom og til leukæmi |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18157714.9T DK3345611T3 (da) | 2012-12-31 | 2013-12-31 | Støtteterapi til erhvervet immundefektsyndrom og til leukæmi |
Country Status (13)
Country | Link |
---|---|
US (2) | US10933105B2 (da) |
EP (2) | EP3345611B1 (da) |
KR (1) | KR102188696B1 (da) |
CN (1) | CN105025908A (da) |
BR (1) | BR112015015393A2 (da) |
CA (1) | CA2896402A1 (da) |
DK (2) | DK2938349T3 (da) |
ES (1) | ES2668483T3 (da) |
IT (1) | ITMI20122270A1 (da) |
PL (1) | PL2938349T3 (da) |
PT (1) | PT2938349T (da) |
RU (2) | RU2018141041A (da) |
WO (1) | WO2014102595A1 (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20122270A1 (it) | 2012-12-31 | 2014-07-01 | Giovanni Mogna | Terapia di supporto ai trattamenti di chemioterapia per i tumori, per la sindrome da immunodeficienza acquisita e per le leucemie. |
KR101693574B1 (ko) * | 2014-09-23 | 2017-01-06 | 한국 한의학 연구원 | 틴달화 유산균 사균체를 유효성분으로 포함하는 피부 보습 또는 주름개선용 조성물 |
KR102244492B1 (ko) * | 2020-10-21 | 2021-04-26 | 대한민국(관리부서:국립수산과학원) | 신규 락토바실러스 속 균주 및 그의 용도 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950001449B1 (ko) * | 1992-07-03 | 1995-02-24 | 풀무원식품주식회사 | 알로에를 주원료로 한 건강보조식품의 제조방법 |
US7122370B2 (en) * | 2003-01-14 | 2006-10-17 | Randolph Stanley Porubcan | Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life |
ATE361101T1 (de) | 2004-08-24 | 2007-05-15 | Nutricia Nv | Nahrungszusammensetzung die unverdauliche oligosaccharide enthält |
US20060045887A1 (en) * | 2004-08-25 | 2006-03-02 | Gavish-Galilee Bio Applications Ltd. | Mushroom extracts having anticancer activity |
US7964571B2 (en) * | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
US7329421B2 (en) * | 2004-12-16 | 2008-02-12 | Agashe Mandar Dnyaneshwar | Process of manufacturing clear juice from the leaves of the Aloe vera plant |
ITMI20051510A1 (it) | 2005-08-02 | 2007-02-03 | Proge Farm Srl | Uso di specifici batteri lattici per la preparazione di composizioni iunomodulanti |
ITTO20070555A1 (it) | 2007-07-26 | 2009-01-27 | Bioman S R L | Biomassa arricchita in zinco, procedimento per la sua preparazione e prodotti probiotici, cosmetici, dietetici e nutraceutici comprendenti tale biomassa |
ITBA20080008A1 (it) * | 2008-02-22 | 2009-08-23 | Michele Barone | Composizioni comprendenti fitoestrogeni selettivi per il recettore estrogenico beta e fibre dietetiche |
IT1397566B1 (it) * | 2009-05-27 | 2013-01-16 | Probiotical Spa | Lactobacillus pentosus produttore di batteriocine, composizioni alimentari e farmaceutiche contenenti lo stesso e relativo uso |
US20110117210A1 (en) * | 2009-11-17 | 2011-05-19 | Andrey Ugolkov | Therapeutic treatment of human cancers using simple salts of zinc |
IT1398553B1 (it) * | 2010-03-08 | 2013-03-01 | Probiotical Spa | Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario. |
ITMI20122270A1 (it) | 2012-12-31 | 2014-07-01 | Giovanni Mogna | Terapia di supporto ai trattamenti di chemioterapia per i tumori, per la sindrome da immunodeficienza acquisita e per le leucemie. |
-
2012
- 2012-12-31 IT IT002270A patent/ITMI20122270A1/it unknown
-
2013
- 2013-12-31 ES ES13828803.0T patent/ES2668483T3/es active Active
- 2013-12-31 PL PL13828803T patent/PL2938349T3/pl unknown
- 2013-12-31 BR BR112015015393A patent/BR112015015393A2/pt not_active IP Right Cessation
- 2013-12-31 US US14/758,211 patent/US10933105B2/en active Active
- 2013-12-31 RU RU2018141041A patent/RU2018141041A/ru not_active Application Discontinuation
- 2013-12-31 CA CA2896402A patent/CA2896402A1/en not_active Abandoned
- 2013-12-31 DK DK13828803.0T patent/DK2938349T3/da active
- 2013-12-31 WO PCT/IB2013/002890 patent/WO2014102595A1/en active Application Filing
- 2013-12-31 DK DK18157714.9T patent/DK3345611T3/da active
- 2013-12-31 EP EP18157714.9A patent/EP3345611B1/en active Active
- 2013-12-31 CN CN201380068989.3A patent/CN105025908A/zh active Pending
- 2013-12-31 EP EP13828803.0A patent/EP2938349B1/en active Active
- 2013-12-31 RU RU2015124336A patent/RU2674658C2/ru not_active IP Right Cessation
- 2013-12-31 KR KR1020157020418A patent/KR102188696B1/ko active IP Right Grant
- 2013-12-31 PT PT138288030T patent/PT2938349T/pt unknown
-
2020
- 2020-02-27 US US16/803,874 patent/US20200197453A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2938349B1 (en) | 2018-02-21 |
RU2015124336A (ru) | 2017-02-06 |
CA2896402A1 (en) | 2014-07-03 |
EP2938349A1 (en) | 2015-11-04 |
DK3345611T3 (da) | 2020-11-30 |
KR102188696B1 (ko) | 2020-12-09 |
EP3345611B1 (en) | 2020-09-02 |
US10933105B2 (en) | 2021-03-02 |
EP3345611A1 (en) | 2018-07-11 |
WO2014102595A1 (en) | 2014-07-03 |
ES2668483T3 (es) | 2018-05-18 |
RU2018141041A (ru) | 2019-03-21 |
KR20150102102A (ko) | 2015-09-04 |
US20200197453A1 (en) | 2020-06-25 |
PL2938349T3 (pl) | 2018-08-31 |
PT2938349T (pt) | 2018-04-26 |
CN105025908A (zh) | 2015-11-04 |
RU2674658C2 (ru) | 2018-12-12 |
ITMI20122270A1 (it) | 2014-07-01 |
BR112015015393A2 (pt) | 2017-07-11 |
US20150343004A1 (en) | 2015-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2713414C2 (ru) | Композиция для применения в лечении или предупреждении вирусных или бактериальных инфекций у субъекта, проходящего противоопухолевую химиотерапию, лечение лейкоза или лечение СПИД, содержащая l.reuteri ler03 и/или l.salivarius ls06 | |
Ren et al. | Evaluation of immunomodulatory activity of two potential probiotic Lactobacillus strains by in vivo tests | |
Shigwedha | Probiotical cell fragments (PCFs) as “novel nutraceutical ingredients” | |
US20200197453A1 (en) | Composition for use as a support therapy for treatment of tumours, aids and leukaemia | |
RU2721565C2 (ru) | Терапевтическое средство для применения в лечении опухолей, синдрома приобретенного иммунодефицита и лейкозов путем двойной иммунной биостимуляции | |
Domingos-Lopes et al. | Immunomodulatory activity of exopolysaccharide producing Leuconostoc citreum strain isolated from Pico cheese | |
Kim et al. | The effect of Lactobacillus casei extract on cervical cancer cell lines | |
Zhu et al. | Immunomodulatory effects of novel bifidobacterium and lactobacillus strains on murine macrophage cells | |
Sim et al. | The ameliorative role of probiotics in 5-fluorouracil induced intestinal mucositis | |
Lazarenko et al. | Imunobiotics are the novel biotech drugs with antibacterial and immunomodulatory properties | |
Javid et al. | Probiotics as an adjuvant for management of gastrointestinal cancers through their anti-inflammatory effects: a mechanistic review | |
Delesa | Overview of anticancer activity of lactic acid bacteria | |
JP2015120651A (ja) | 抗腫瘍剤及びその製造方法 | |
Bamola et al. | Probiotics and Immunomodulation | |
ITRM20130174A1 (it) | Ceppo di lactobacillus e suo uso come probiotico |